Puerarin enhances proliferation and osteoblastic differentiation of human bone marrow stromal cells via a nitric oxide/cyclic guanosine monophosphate signaling pathway

Lv,Haihong; Che,Tuanjie; Tang,Xulei; Liu,Lijuan; Cheng,Jianguo

doi:10.3892/mmr.2015.3647

Puerarin enhances proliferation and osteoblastic differentiation of human bone marrow stromal cells via a nitric oxide/cyclic guanosine monophosphate signaling pathway

Authors:
- Haihong Lv
- Tuanjie Che
- Xulei Tang
- Lijuan Liu
- Jianguo Cheng
View Affiliations

Affiliations: Department of Endocrinology and Metabolism, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Baiyuan Gene Technology Co. Ltd, Lanzhou, Gansu 730000, P.R. China
Published online on: April 20, 2015 https://doi.org/10.3892/mmr.2015.3647
Pages: 2283-2290

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Puerarin, a major active isoflavone extracted from the Traditional Chinese Medicine Radix Puerariae, has been studied for its comprehensive biological effects. However, to date, its effect on bone formation and the underlying mechanism of action have not been well investigated. The present study investigated the effect of puerarin on cell proliferation and osteoblastic maturation in cultured human bone marrow stromal cells (hBMSC) in vitro. Puerarin (2.5‑100 µM) increased hBMSC growth in a dose‑dependent manner, as indicated by an MTT assay, and stimulated osteoblastic maturation as indicated by assessment of alkaline phosphatase (ALP) activity, as well as calcium deposition into the extracellular matrix detected by alizarin red S staining. Furthermore, polymerase chain reaction analysis showed that the expression of osteoblastic markers, including Runt-related transcription factor 2/core-binding factor alpha 1, osterix and osteocalcin, were increased in hBMSCs following incubation with puerarin. Further experiments indicated that puerarin increased the nitric oxide (NO) production and cyclic guanosine monophosphate (cGMP) content in hBMSCs. The effects of puerarin were mimicked by 17β‑estrodiol (10‑8 M) and were abolished in the presence of estrogen receptor antagonist ICI182780 (10‑7 M). A NO synthase inhibitor, Nx‑nitro‑L‑arginine methylester (6x10‑3 M), significantly attenuated puerarin‑induced increases in NO production and cGMP content, in parallel with a reduction of cell proliferation and osteoblastic differentiation as well as the expression of osteoblastic markers. These results suggested that puerarin may prevent osteoporosis by exerting stimulatory effects on bone formation and the NO/cGMP pathway, which has an important role in puerarin‑induced hBMSC proliferation and osteoblastic differentiation.

View Figures

View References

1	Corina M, Vulpoi C and Brănişteanu D: Relationship between bone mineral density, weight, and estrogen levels in pre and postmenopausal women. Rev Med Chir Soc Med Nat lasi. 116:946–950. 2012.
2	Han KO, Moon IG, Kang YS, et al: Nonassociation of estrogen receptor genotypes with bone mineral density and estrogen responsiveness to hormone replacement therapy in Korean postmenopausal women. J Clin Endocrinol Metab. 82:991–995. 1997. View Article : Google Scholar : PubMed/NCBI
3	Turner C: Hormone replacement therapy: its use in the management of acute menopausal symptoms. J Am Acad Nurse Pract. 6:318–320. 1994. View Article : Google Scholar : PubMed/NCBI
4	Palacios S, Christiansen C, Sánchez Borrego R, et al: Recommendations on the management of fragility fracture risk in women younger than 70 years. Gynecol Endocrinol. 28:770–786. 2012. View Article : Google Scholar : PubMed/NCBI
5	Lees B and Stevenson JC: The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone. Osteoporos Int. 12:251–258. 2001. View Article : Google Scholar : PubMed/NCBI
6	Kaya C, Dinçer Cengiz S, Cengiz B and Akgün G: The long-term effects of low-dose 17beta-estradiol and dydrogesterone hormone replacement therapy on 24 h ambulatory blood pressure in hypertensive postmenopausal women: a 1-year randomized, prospective study. Climacteric. 9:437–445. 2006. View Article : Google Scholar : PubMed/NCBI
7	Popp AW, Bodmer C, Senn C, et al: Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy. Maturitas. 53:191–200. 2006. View Article : Google Scholar
8	Pike MC and Ross RK: Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids. 65:659–664. 2000. View Article : Google Scholar : PubMed/NCBI
9	Boué SM, Wiese TE, Nehls S, et al: Evaluation of the estrogenic effects of legume extracts containing phytoestrogens. J Agric Food Chem. 51:2193–2199. 2003. View Article : Google Scholar : PubMed/NCBI
10	Chen L and Lu ZP: Randomized controlled trial of integrated traditional Chinese and western medicine treatment for posthepatitic cirrhotic ascites: a systematic review. Chin J Hepatol. 19:205–209. 2011.In Chinese.
11	Lagari VS and Levis S: Phytoestrogens in the prevention of postmenopausal bone loss. J Clin Densitom. 16:445–449. 2013. View Article : Google Scholar : PubMed/NCBI
12	Chen Z, Lin SY, Zhou YH, et al: Analysis of clinical features of traditional Chinese medicine symptoms and syndromes of 220 patients with chronic aplastic anemia. Chin J Integr Tradit West Med. 34:43–45. 2014.In Chinese.
13	Boué SM, Burow ME, Wiese TE, et al: Estrogenic and anti-estrogenic activities of phytoalexins from red kidney bean (Phaseolus vulgaris L.). J Agric Food Chem. 59:112–120. 2011. View Article : Google Scholar
14	Wang Y, Wang WL, Xie WL, Li LZ, Sun J, Sun WJ and Gong HY: Puerarin stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/Akt activation. Phytomedicine. 20:787–796. 2013. View Article : Google Scholar : PubMed/NCBI
15	Armour KJ, Armour KE, van’t Hof RJ, Reid DM, Wei XQ, Liew FY and Ralston SH: Activation of the inducible nitric oxide synthase pathway contributes to inflammation-induced osteoporosis by suppressing bone formation and causing osteoblast apoptosis. Arthritis Rheum. 44:2790–2796. 2001. View Article : Google Scholar
16	Samuels A, Perry MJ, Gibson RL, Colley S and Tobias JH: Role of endothelial nitric oxide synthase in estrogen-induced osteogenesis. Bone. 29:24–29. 2001. View Article : Google Scholar : PubMed/NCBI
17	Wang DH, Hu YS, Du JJ, et al: Ghrelin stimulates proliferation of human osteoblastic TE85 cells via NO/cGMP signaling pathway. Endocrine. 35:112–117. 2008. View Article : Google Scholar : PubMed/NCBI
18	El-Mowafy AM, Alkhalaf M and Jaffal SM: Nongenomic activation of the GC-A enzyme by resveratrol and estradiol downstream from membrane estrogen receptors in human coronary arterial cells. Nutr Metab Cardiovasc Dis. 17:508–516. 2007. View Article : Google Scholar
19	Pan W, Quarles LD, Song LH, et al: Genistein stimulates the osteoblastic differentiation via NO/cGMP in bone marrow culture. J Cell Biochem. 94:307–316. 2005. View Article : Google Scholar
20	Andelman F, Kipervasser S, Maimon S, Fried I, Parmet Y and Neufeld MY: A revised intracarotid etomidate memory (Wada) procedure. Acta Neurol Scand. 127:97–102. 2013. View Article : Google Scholar
21	Hokazono E, Osawa S, Nakano T, et al: Development of a new measurement method for serum calcium with chlorophosphonazo-III. Ann Clin Biochem. 46:296–301. 2009. View Article : Google Scholar : PubMed/NCBI
22	Holzer G, Einhorn TA and Majeska RJ: Estrogen regulation of growth and alkaline phosphatase expression by cultured human bone marrow stromal cells. J Orthop Res. 20:281–288. 2002. View Article : Google Scholar : PubMed/NCBI
23	Almeida M, Martin-Millan M, Ambrogini E, et al: Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERalpha. J Bone Miner Res. 25:769–781. 2010.
24	MacIntyre I, Zaidi M, Alam AS, Datta HK, Moonga BS, Lidbury PS, Hecker M and Vane JR: Osteoclast inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci USA. 88:2936–2940. 1991. View Article : Google Scholar
25	Galea GL, Meakin LB, Sugiyama T, et al: Estrogen receptor α mediates proliferation of osteoblastic cells stimulated by estrogen and mechanical strain, but their acute down-regulation of the Wnt antagonist Sost is mediated by estrogen receptor β. J Biol Chem. 288:9035–9048. 2013. View Article : Google Scholar : PubMed/NCBI
26	Turner RT, Evans GL and WakIey GK: Mechanism of action of estrogen on cancellous bone balance in tibiae of ovariectomized growing rat: Inhibition of indices of formation and resorption. J Bone Miner Res. 8:359–366. 1993. View Article : Google Scholar : PubMed/NCBI
27	Wang Q, Sun L, Zhang F, et al: Effects of 17β-estradiol on cell proliferation, cAMP and cGMP content and iNOS activity in human osteoblast-like osteosarcoma cell line TE85. Chin Pharmacol Bull. 14:314–317. 1998.
28	Cervellati C, Bonaccorsi G, Cremonini E, et al: Oxidative stress and bone resorption interplay as a possible trigger for postmenopausal osteoporosis. Biomed Res Int. 2014:563–569. 2014. View Article : Google Scholar
29	Manolagas SC, O’Brien CA and Almeida M: The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 9:699–712. 2013. View Article : Google Scholar : PubMed/NCBI
30	Michihara S, Tanaka T, Uzawa Y, Moriyama T and Kawamura Y: Puerarin exerted anti-osteoporotic action independent of estrogen receptor-mediated pathway. J Nutr Sci Vitaminol (Tokyo). 58:202–209. 2012. View Article : Google Scholar
31	Saha P, Saraswat G, Chakraborty P, Banerjee S, Pal BC and Kabir SN: Puerarin, a selective oestrogen receptor modulator, disrupts pregnancy in rats at pre-implantation stage. Reproduction. 144:633–645. 2012. View Article : Google Scholar : PubMed/NCBI
32	Deng Y, Ng ES, Yeung JH, et al: Mechanisms of the cerebral vasodilator actions of isoflavonoids of Gegen on rat isolated basilar artery. J Ethnopharmacol. 139:294–304. 2012. View Article : Google Scholar
33	Sheu SY, Tsai CC, Sun JS, Chen MH, Liu MH and Sun MG: Stimulatory effect of puerarin on bone formation through co-activation of nitric oxide and bone morphogenetic protein-2/mitogen-activated protein kinases pathways in mice. Chin Med J (Engl). 125:3646–3653. 2012.
34	Brown JP, Dempster DW, Ding B, Dent-Acosta R, San Martin J, Grauer A, Wagman RB and Zanchetta J: Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study. J Bone Miner Res. 26:2737–2744. 2011. View Article : Google Scholar : PubMed/NCBI
35	Rangaswami HI, Marathe N, Zhuang S, et al: Type II cGMP-dependent protein kinase mediates osteoblast mechano-transduction. Handb Exp Pharmacol. 191:137–162. 2009.
36	Pfeifer A, Aszódi A, Seidler U, Ruth P, Hofmann F and Fässler R: Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinase II. Science. 274:2082–2086. 1996. View Article : Google Scholar : PubMed/NCBI
37	Wimalawansa SJ: Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans. Ann NY Acad Sci. 1117:283–297. 2007. View Article : Google Scholar : PubMed/NCBI
38	Yang F, Zhang R, He F, Wang XX, Zhao S and Yang G: Osteoblast response to puerarin-loaded porous titanium surfaces: an in vitro study. J Biomed Mater Res A. 100:1419–1426. 2012. View Article : Google Scholar : PubMed/NCBI
39	Wang N, Wang X, Cheng W, et al: Puerarin promotes osteogenesis and inhibits adipogenesis in vitro. Chin Med. 8:172013. View Article : Google Scholar : PubMed/NCBI
40	Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC and Meunier PJ: Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1:1091–1093. 1984. View Article : Google Scholar : PubMed/NCBI
41	Minisola S, Rosso R, Romagnoli E, et al: Serum osteocalcin and bone mineral density at various skeletal sites: a study performed with three different assays. J Lab Clin Med. 129:422–429. 1997. View Article : Google Scholar : PubMed/NCBI
42	Koo KT, Lee SW, Lee MH, Kim KH, Jung SH and Kang YG: Time-dependent expression of osteoblast marker genes in human primary cells cultured on microgrooved titanium substrata. Clin Oral Implants Res. 25:714–722. 2014. View Article : Google Scholar